Phase I/II study of LYS-GM101 for treatment of GM1 Gangliosidosis

Trial Profile

Phase I/II study of LYS-GM101 for treatment of GM1 Gangliosidosis

Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 May 2017

At a glance

  • Drugs LYS GM101 (Primary)
  • Indications Gangliosidoses
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 May 2017 According to a Lysogene media release, the phase I trial is expected to begin in 2019.
    • 02 Feb 2017 According to a LYSOGENE media release, company is planning to start this trial by the end of the first half of 2018.
    • 20 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top